Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1947 1
1948 2
1949 2
1950 4
1951 10
1952 15
1953 12
1954 11
1955 13
1956 8
1957 12
1958 6
1959 2
1960 4
1961 1
1962 5
1964 3
1965 3
1966 2
1967 7
1968 7
1969 9
1970 12
1971 17
1972 12
1973 20
1974 27
1975 90
1976 81
1977 102
1978 110
1979 144
1980 158
1981 155
1982 146
1983 161
1984 169
1985 190
1986 182
1987 191
1988 192
1989 184
1990 172
1991 187
1992 164
1993 139
1994 150
1995 159
1996 138
1997 122
1998 118
1999 137
2000 125
2001 118
2002 97
2003 121
2004 116
2005 129
2006 143
2007 142
2008 153
2009 154
2010 152
2011 174
2012 204
2013 220
2014 227
2015 216
2016 238
2017 214
2018 224
2019 225
2020 170
Text availability
Article attribute
Article type
Publication date

Search Results

7,164 results
Results by year
Filters applied: . Clear all
Page 1
A small-molecule inhibitor of C5 complement protein.
Jendza K, Kato M, Salcius M, Srinivas H, De Erkenez A, Nguyen A, McLaughlin D, Be C, Wiesmann C, Murphy J, Bolduc P, Mogi M, Duca J, Namil A, Capparelli M, Darsigny V, Meredith E, Tichkule R, Ferrara L, Heyder J, Liu F, Horton PA, Romanowski MJ, Schirle M, Mainolfi N, Anderson K, Michaud GA. Jendza K, et al. Nat Chem Biol. 2019 Jul;15(7):666-668. doi: 10.1038/s41589-019-0303-9. Epub 2019 Jun 17. Nat Chem Biol. 2019. PMID: 31209353
The human complement component 5 protein (C5) is a validated drug target within the complement pathway, as an anti-C5 antibody (Soliris) is an approved therapy for paroxysmal nocturnal hemoglobinuria. Here, we report the identification, optimization an …
The human complement component 5 protein (C5) is a validated drug target within the complement pathway, as an anti-C
An inhibitor of complement C5 provides structural insights into activation.
Reichhardt MP, Johnson S, Tang T, Morgan T, Tebeka N, Popitsch N, Deme JC, Jore MM, Lea SM. Reichhardt MP, et al. Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):362-370. doi: 10.1073/pnas.1909973116. Epub 2019 Dec 23. Proc Natl Acad Sci U S A. 2020. PMID: 31871188 Free PMC article.
We show direct binding of a CirpT to complement C5 and have determined the structure of the C5-CirpT complex by cryoelectron microscopy. ...Analysis of the binding interface reveals a mechanism of C5 inhibition, and provides information to expand our b …
We show direct binding of a CirpT to complement C5 and have determined the structure of the C5-CirpT complex by cryoele …
Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System.
Carpanini SM, Torvell M, Morgan BP. Carpanini SM, et al. Front Immunol. 2019 Mar 4;10:362. doi: 10.3389/fimmu.2019.00362. eCollection 2019. Front Immunol. 2019. PMID: 30886620 Free PMC article. Review.
The complement system plays critical roles in development, homeostasis, and regeneration in the central nervous system (CNS) throughout life; however, complement dysregulation in the CNS can lead to damage and disease. ...There have been a few recent clinical trials …
The complement system plays critical roles in development, homeostasis, and regeneration in the central nervous system (CNS) througho …
Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.
Fukuzawa T, Sampei Z, Haraya K, Ruike Y, Shida-Kawazoe M, Shimizu Y, Gan SW, Irie M, Tsuboi Y, Tai H, Sakiyama T, Sakamoto A, Ishii S, Maeda A, Iwayanagi Y, Shibahara N, Shibuya M, Nakamura G, Nambu T, Hayasaka A, Mimoto F, Okura Y, Hori Y, Habu K, Wada M, Miura T, Tachibana T, Honda K, Tsunoda H, Kitazawa T, Kawabe Y, Igawa T, Hattori K, Nezu J. Fukuzawa T, et al. Sci Rep. 2017 Apr 24;7(1):1080. doi: 10.1038/s41598-017-01087-7. Sci Rep. 2017. PMID: 28439081 Free PMC article.
In cynomolgus monkeys, SKY59 suppressed C5 function and complement activity for a significantly longer duration compared to a conventional antibody. ...Collectively, these results suggest that SKY59 is a promising new anti-C5 agent for patients with PNH and o …
In cynomolgus monkeys, SKY59 suppressed C5 function and complement activity for a significantly longer duration compared to a …
Structural basis for therapeutic inhibition of complement C5.
Jore MM, Johnson S, Sheppard D, Barber NM, Li YI, Nunn MA, Elmlund H, Lea SM. Jore MM, et al. Nat Struct Mol Biol. 2016 May;23(5):378-86. doi: 10.1038/nsmb.3196. Epub 2016 Mar 28. Nat Struct Mol Biol. 2016. PMID: 27018802 Free PMC article.
Activation of complement C5 generates the potent anaphylatoxin C5a and leads to pathogen lysis, inflammation and cell damage. ...Here we identify and characterize a new protein family of tick-derived C5 inhibitors. Structures of C5 in complex with the …
Activation of complement C5 generates the potent anaphylatoxin C5a and leads to pathogen lysis, inflammation and cell damage. …
Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management.
Sridharan M, Go RS, Willrich MAV. Sridharan M, et al. J Immunol Methods. 2018 Oct;461:15-22. doi: 10.1016/j.jim.2018.07.006. Epub 2018 Jul 19. J Immunol Methods. 2018. PMID: 30031798 Review.
One type of TMA is atypical hemolytic uremic syndrome (aHUS) a disorder caused by hyper-activation of the alternative complement pathway due to over activation of C3 convertases and loss of complement regulatory mechanisms. ...For those, another option for treatment …
One type of TMA is atypical hemolytic uremic syndrome (aHUS) a disorder caused by hyper-activation of the alternative complement path …
Complement factor C5 in Atlantic salmon (Salmo salar): Characterization of cDNA, protein and glycosylation.
Johansen W, Grove S, Anonsen JH, Moen A, Agusti-Ridaura C, Azar AS, Strætkvern KO. Johansen W, et al. Dev Comp Immunol. 2019 Nov;100:103424. doi: 10.1016/j.dci.2019.103424. Epub 2019 Jun 26. Dev Comp Immunol. 2019. PMID: 31254563 Free article.
Complement component 5 (C5) is an essential factor of the defensive complement system in all vertebrates. We report the characterization of C5 cDNA and protein from Atlantic salmon (Salmo salar), a teleost fish species of high importance in aquaculture
Complement component 5 (C5) is an essential factor of the defensive complement system in all vertebrates. We report the
Characterizing a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis.
Zelek WM, Stott M, Walters D, Harris CL, Morgan BP. Zelek WM, et al. Immunology. 2018 Nov;155(3):396-403. doi: 10.1111/imm.12982. Epub 2018 Jul 30. Immunology. 2018. PMID: 29981529 Free PMC article.
C5 plays a major role in complement activation; C5 convertase cleaves C5 into the pro-inflammatory C5a, and C5b, the nidus for the formation of the lytic membrane attack complex. C5 is a major target for anti-complement drugs, necessitati
C5 plays a major role in complement activation; C5 convertase cleaves C5 into the pro-inflammatory C5a, and C5b,
Eculizumab epitope on complement C5: Progress towards a better understanding of the mechanism of action.
Brachet G, Bourquard T, Gallay N, Reiter E, Gouilleux-Gruart V, Poupon A, Watier H. Brachet G, et al. Mol Immunol. 2016 Sep;77:126-31. doi: 10.1016/j.molimm.2016.07.016. Epub 2016 Aug 5. Mol Immunol. 2016. PMID: 27497837
Eculizumab is an anti-complement C5 monoclonal antibody which has greatly improved the prognosis and outcomes of nocturnal paroxysmal hemoglobinuria and atypical hemolytic and uremic syndromes. ...Sequence analysis, in silico docking and reverse phase protein array …
Eculizumab is an anti-complement C5 monoclonal antibody which has greatly improved the prognosis and outcomes of nocturnal par …
The rational design of affinity-attenuated OmCI for the purification of complement C5.
Macpherson A, Liu X, Dedi N, Kennedy J, Carrington B, Durrant O, Heywood S, van den Elsen J, Lawson ADG. Macpherson A, et al. J Biol Chem. 2018 Sep 7;293(36):14112-14121. doi: 10.1074/jbc.RA118.004043. Epub 2018 Jul 20. J Biol Chem. 2018. PMID: 30030376 Free PMC article.
Complement component C5 is the target of the mAb eculizumab and is the focus of a sustained drug discovery effort to prevent complement-induced inflammation in a range of autoimmune diseases. The immune evasion protein OmCI binds to and potently inactivates
Complement component C5 is the target of the mAb eculizumab and is the focus of a sustained drug discovery effort to prevent
7,164 results
Jump to page
Feedback